ArticleNature communications2025
Two-stage CD8
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The development of single-cell lineage tracing technology and its application in immunotherapy.Molecular therapy. Advances · 2026Review
- Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.Cancer immunology research · 2026Article
- Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.Nature reviews. Clinical oncology · 2026Review
- Class I HDAC inhibition enhances the stem-like memory properties of CRISPR-engineered CAR T cells in neuroblastoma.Molecular therapy. Oncology · 2026Article
- Article
- In vivo CAR-T therapy: from molecular design to precision delivery.Journal of nanobiotechnology · 2026Review
- Biomarker-empowered precision navigation of CAR-T cell therapy.Molecular cancer · 2026Review
- Polymer-lipid hybrid nanoparticle enhances mRNA delivery and T cell-mediated immunity.bioRxiv : the preprint server for biology · 2026Article
- The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer.Frontiers in immunology · 2026Review
- CAR T cell persistence in cancer.Trends in cancer · 2025Review
- Current Insights of Post-Infusion CAR T Expansion and Persistence for Large B-Cell Lymphoma.Cancers · 2025Review
- ITK overexpression enhances T cell cytotoxicity against DLBCL through the TCR-CaScientific reports · 2025Article
- Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
- Update ofTwo-Stage CD82025
Authors and funding
11 authors.
Funding
Abstract
Advancements in chimeric antigen receptor (CAR) T-cell therapy for treating diffuse large B-cell lymphoma (DLBCL) have been limited by an incomplete understanding of CAR T-cell differentiation in patients. Here, we show via single-cell, multi-modal, and longitudinal analyses, that CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.